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Summary 
The basic helix-loop-helix (bHLH) protein E2-2 is known to play a role in 
quiescence of endothelial cells (ECs). However, how the activity of E2-2 is controlled 
in the cells is still unclear. In this study, we identified FAM96B as an interaction 
partner of E2-2. FAM96B interfered with E2-2-mediated effects on luciferase 
reporter activities. Furthermore, the suppression of VEGFR2 promoter activity by 
E2-2 was rescued by the expression of FAM96B in a dose-dependent manner. 
Interestingly, FAM96B decreased the expression of ectopic and endogenous E2-2 
proteins. Mutational analysis revealed that the middle region of FAM96B is 
required for the limited expression of E2-2 protein. When FAM96B was expressed 
in ECs, the EC migration, proliferation and tube formation were potentiated. Taken 
together, these findings suggest that FAM96B acts as a regulator of E2-2 via the 
control of its protein expression.  
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Introduction 
The basic-helix-loop-helix (bHLH) protein E2-2, alternatively termed ITF2, 
TCF4, SEF2, and SEF2-1B, was originally identified as a transcription factor that binds 
to the µE5 and κE2 motifs in the immunoglobulin heavy and light chain enhancers, 
respectively (1). Together with E12/47 and HEB, E2-2 belongs to the E protein family. E 
proteins are widely expressed in tissues and bind to consensus DNA sequences 
containing (G/A)CAXXTG(G/A) as either homodimers or heterodimers with other HLH 
family molecules (2,3). The E protein family is known to regulate lymphocyte 
development (4), neural differentiation (5), and myogenesis (6). Recently, we and another 
group demonstrated that E proteins also regulate blood vessel formation (7-9). 
The activity of E proteins is known to be controlled via their interaction with 
other HLH proteins (10), coactivators (11,12), or corepressors (13) as well as via their 
own phosphorylation (14). The Id family, which lacks the basic region important for 
DNA binding activity, associates with E proteins to inhibit their DNA binding activity 
(10). The coactivators CBP and p300 interact with E proteins via their AD1 domain to 
potentiate their transcriptional activity (11,12), although the ETO family blocks the 
transcriptional activity of E proteins via its direct interaction (13).  
Angiogenesis, the formation of new blood vessels, is crucial for vascular 
development and homeostasis. Aberrant vascularization leads us to a number of diseases 
including atherosclerosis, tumorigenicity, and retinopathy. Angiogenesis occurs by 
sprouting of new vessels from preexisting ones or by intussusceptive microvascular 
growth. Thus, angiogenesis is essential during embryonic development as well as in 
adulthood. In general, vascular formation is quiet in adulthood although angiogenesis 
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involved in wound healing, inflammation, ischemia, and the female reproductive cycle 
has been observed (15). Angiogenesis is divided into two phases: the activation phase and 
the resolution phase. The angiogenic switch depends on a finely tuned balance between 
stimulators (VEGF, FGF-2, angiopoietins, hypoxia, and so on) and inhibitors (angiostatin, 
endostatin, interferon-α, and so on). During the activation phase, proliferation of 
endothelial cells (ECs), increase of vascular permeability, and degradation of 
extracellular matrix components can be observed. Consequently, ECs make new capillary 
sprouts. During the resolution phase, the proliferation and migration of ECs stops, 
whereafter the basement membrane is reconstituted and the vessels mature (16).   
In our recent studies, E2-2 as well as E2A inhibited the activity of the VEGFR2 
promoter to inhibit the activity of endothelium in vivo and in vitro. In contrast, Id1 and 
SCL/TAL1, both of which possess the HLH domains, relieved E2-2-mediated inhibition 
of VEGFR2 promoter activity because of heterodimer formation with E2-2 (7,8). 
However, partner(s) other than HLH-containing proteins can still regulate the activity of 
E2-2.  
To gain more insight into the molecular mechanisms by which E2-2 suppresses 
the activity of endothelium, we surveyed its interaction partner(s) and identified 
FAM96B, alternatively named CGI-128. However, its function has yet to be identified. In 
this study, we explored the regulatory role of FAM96B on the function of E2-2. In 
addition, we examined its function in EC activation. We found that FAM96B promoted 
decrease of E2-2 protein to rescue E2-2-mediated repression of VEGFR2 promoter 
activity. Consequently, FAM96B concomitantly enhanced EC migration, proliferation 
and tube formation. 
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Material and Methods 
Plasmids and adenoviruses 
The cDNA for human FAM96B was cloned by RT-PCR and sequenced to be verified 
prior to use. FAM96B(42-121) and FAM96B∆ (42-121) were generated by Pfx DNA 
polymerase (Invitrogen) using human FAM96B as the template. Subsequently, each 
DNA was ligated into either Flag-pDEF3 or Myc-pDEF3 (17). Myc-E2-2 and Flag-E2-2 
have been previously described (8). MCKpfos-luc was generously provided by Dr. M. 
Sigvardsson (18), and pGL2b-VEGFR2-luc (-166bp/+267bp) by Dr. C. C. W. Hughes 
(19). Adenovirus expressing Myc-FAM96B was generated using the pAdTrack-CMV 
vector (20). After pAdTrack-CMV-Myc-FAM96B was recombined with pAdEasy-1 (20), 
the resulting plasmid was transfected into 293T cells, and the adenoviruses were 
amplified. LacZ- and constitutively active activin receptor-like kinase 6 
(ALK6ca)/HA-expressing adenoviruses are previously described (8). 
Cell culture 
COS7 cells, NIH3T3 cells, and mouse embryonic endothelial cells (MEECs) (21) were 
maintained in Dulbecco’s modified Eagle’s media (DMEM, Sigma) containing 10% fetal 
calf serum (FCS, Gibco), 1X MEM nonessential amino acids (NEAA, Invitrogen), and 
100 U/mL penicillin/streptomycin. Calf pulmonary artery epithelial cells (CPAEs) (22) 
were cultured in DMEM with 10% FCS, 20 mM HEPES, and 100 U/mL 
penicillin/streptomycin. Primary human umbilical vein endothelial cells (HUVECs) were 
cultured in EBM (TAKARA) supplemented with 2% FCS. MEECs and HUVECs were 
grown on 0.1% gelatin-coated dishes.  
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Adenoviral infections 
Adenoviruses were incubated in DMEM containing polybrene (80 µg/mL) for 2 h and 
added to the dishes. Two hours after infection, the cells were washed and allowed to 
recover for 24 h prior to the experiments. 
Immunoprecipitation and Western blotting 
To detect interactions among proteins, plasmids were transfected into COS7 cells (5 x 105 
cells/6-cm dish) using FuGENE6 (Roche). Forty hours after the transfection, the cells 
were lysed in 500 µL of TNE buffer (10 mM Tris [pH 7.4], 150 mM NaCl, 1 mM 
ethylenediamine-N’, N’, N’, N’-tetraaccetic acid [EDTA], 1% NP-40, 1 mM 
phenylmethylsulfonyl-l-fluoride [PMSF], 5 µg/mL leupeptin, 100 U/mL aprotinin, 2 mM 
sodium vanadate, 40 mM NaF, and 20 mM β-glycerophosphate). The cell lysates were 
precleared with protein G sepharose beads (GE Healthcare) for 30 min at 4°C and then 
incubated with anti-Flag M5 (Sigma), anti-Myc9E10 (SantaCruz), or anti-E2-2 (M03) 
(Abnova) antibody for 2 h at 4°C. Protein complexes were immunoprecipitated by 
incubation with protein G Sepharose beads for 30 min at 4°C and then washed three 
times with TNE buffer. The immunoprecipitated proteins and aliquots of the total cell 
lysates were boiled for 5 min in sample buffer, separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), and transferred to Hybond-C Extra membrane (GE 
Healthcare). The membranes were probed with anti-Myc9E10 or anti-Flag M5 antibody. 
Primary antibodies were detected with horseradish peroxidase-conjugated goat 
anti-mouse antibody (GE Healthcare) and chemiluminescent substrate (Pierce). The 
protein expression in the total cell lysates was evaluated by Western blotting using 
anti-Flag M5, anti-Myc9E10, or anti-E2-2 (M03) antibody. As internal controls, the 
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expressions of β-actin and GFP were detected by using anti-β-actin antibody (Sigma) and 
anti-GFP (SantaCruz) antibody, respectively. 
Immunofluorescence 
MEECs were grown on glass coverslips coated with 0.1% gelatin one day prior to the 
transfection. Cotransfection of Flag-E2-2 with Myc-FAM96B was performed using 
LipofectamineTM (Invitrogen) and PlusTMReagent (Invitrogen). After 40 h, the slips were 
washed with PBS, fixed with 4% paraformaldehyde (PFA) for 10 min, washed three 
times with PBS, permeabilized with 0.1% Triton X-100 (Sigma) for 10 min, and blocked 
with 5% normal swine serum in PBS for 1 h at 37°C. Mouse anti-E2-2 (M03) (1:250) and 
rabbit anti-Myc (1:250) (Upstate Biotechnology) antibodies in 5% normal swine serum in 
PBS were added and incubated for 1 h at 37°C. The slips were washed three times with 
PBS and then incubated with Alexa488-conjugated goat anti-mouse IgG (Molecular 
Probes) or Alexa555-conjugated-goat anti-rabbit IgG (Molecular Probes) at 1:250 for 1 h 
at room temperature. After the nuclei were stained with 2 µg/mL DAPI for 10 min, the 
slips were washed three times with distilled water, and the fluorescent signals visualized 
by microscopy (Zeiss). 
Transcriptional reporter assay 
CPAEs were seeded at 5 x 104 cells/well in 12-well plates one day prior to the 
transfection. The cells were transfected using LipofectamineTM and PlusTMReagent. After 
40 h of transfection, the lysates were prepared and the luciferase activity was measured 
using a luciferase assay system (Promega). The results were corrected for β-galactosidase 
activity (pCH110; GE Healthcare). Each experment was carried out in triplicate and 
repeated at least twice. Values are presented as means ± S. D. (n=3) 
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Migration assay 
Cell migration assays were performed using a Boyden chamber. Costar nucleopore filters 
(8-µm pore) were coated with 10 µg/mL fibronectin (Sigma) overnight at 4°C. The 
chambers were washed three times with PBS. Adenovirus-infected HUVECs starved for 
12 h without FCS were added to the top of each migration chamber at a density of 2.5 x 
105 cells/chamber in 150 µL of EBM without FCS. The cells were allowed to migrate to 
the underside of the chamber. After 24 h, the cells were fixed in 4% PFA and stained with 
0.5% crystal violet (dissolved in 25% methanol). The upper surface was wiped with a 
cotton swab to remove non-migrating cells. Cells present on the lower surface were 
counted. Each experiment was carried out in triplicate and repeated a few times. Values 
are presented as means ± S. D. (n=3). 
Network formation assay 
HUVECs (2 x 104 cells/well in an 8-well Lab-Tek® chamber; ThermoFisher) infected 
with adenoviruses were seeded on growth factor-reduced Matrigel (BD Biosciences, San 
Jose, CA). Images were captured 6 h and 12 h after ECs were seeded (8). The total area 
of tube-like structures formed by HUVECs in each well was measured using Image J 
from NIH. 
Cell proliferation 
Proliferation was measured by the incorporation of [3H]-thymidine to HUVECs. 
HUVECs were seeded in 24-well plates one day before adenoviral infection. Values are 
presented as means ± S. D. (n=3). 
RNA isolation and RT-PCR 
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Total RNA was isolated using the RNeasy kit (QIAGEN, Valencia, CA). Reverse 
transcription was carried out by using a First-Strand cDNA Synthesis Kit (TAKARA). 
PCR was performed using Ex Taq polymerase (TAKARA) as directed by the 
manufacturer. Primer sets used are shown in Supplementary Table I. 
 
Results 
Identification of FAM96B as an interaction partner of E2-2-When we tried to 
identify HLH-interacting protein(s) by the method of yeast two hybrid system using the 
HLH domain of Herp2 as a bait, FAM96B was isolated. Composed of 163 amino acids, 
FAM96B does not possess any known conserved domains. Among HLH proteins 
examined, FAM96B obviously interacted with E2-2 in COS7 cells (Fig. 1a and data not 
shown), although the expression of E2-2 was decreased in the presence of FAM96B (see 
below). This interaction between E2-2 and FAM96B led us to investigate whether E2-2 
colocalizes with FAM96B. After MEECs were transfected with Flag-E2-2 and 
Myc-FAM96B, the subcellular localization was determined by fluorescence microscopy 
by staining E2-2 with Alexa488-conjugated goat anti-mouse IgG and FAM96B with 
Alexa555-conjugated goat anti-rabbit IgG. As seen in Fig. 1b, FAM96B could colocalize 
with E2-2 in the nucleus, which is consistent with an interaction between the two proteins. 
Id1 has been reported to interact with E2-2 to rescue E2-2-mediated inhibition of 
angiogenic reaction (8). Since Id1 induced by BMP or VEGF potentiates angiogenesis 
(8,21,23,24), we tried to test the possibility that the expression of FAM96B is enhanced 
upon BMP or VEGF stimulation. Instead of BMP stimulation, we infected ALK6ca/HA, 
which successively transduces BMP signaling into the cells without the ligands, into cells. 
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As seen in Fig. 1c, FAM96B mRNA was augmented upon BMP signaling in a similar 
fashion to Id1. On the other hand, the expression of E2-2 mRNA was not changed upon 
the ALK6 activation (Suppl. Fig. 1). Furthermore, Id1 mRNA, was induced in endothelial 
cells by VEGF as expected, whereas VEGF did not enhance the expression of FAM96B 
transcript (Suppl. Fig. 2). It remains veiled why the stimulation of BMP, but not that of 
VEGF, accelerated the expression of FAM96B transcript in endothelial cells. We will 
need further exploration in the future experiments. 
Inhibitory effect of FAM96B on E2-2-mediated promoter activity - The 
MCKpfos-luc reporter construct consisting of four E-box elements has been used to 
investigate the function of E proteins (18). Our previous studies reported that Id1 and 
SCL/TAL1, which are interaction partners of E2-2, could counteract E2-2-mediated 
MCKpfos-luc reporter activity (7,8). To examine the possibility that FAM96B affects the 
MCKpfos-luc reporter activity induced by E2-2, we transfected a different amount of 
FAM96B expression vector into the CPAE cells with or without E2-2. FAM96B 
inhibited the E2-2-mediated activity of this reporter in a dose-dependent manner (Figure 
2a) To further confirm that FAM96B influences the transcriptional activity of E2-2, we 
employed the pGL2b-VEGFR2-luc (-166bp/+267bp) luciferase reporter construct, which 
E2-2 negatively controls (7,8). Consistent with the result shown in Fig. 2a, FAM96B 
dose-dependently released the E2-2-mediated inhibition of pGL2b-VEGFR2-luc 
(-166bp/+267bp) luciferase activity (Fig. 2b). These results demonstrated the possibility 
that FAM96B interferes with the transcriptional regulation of E2-2.  
Activation of EC by FAM96B- E2-2 has been reported to hamper the expression 
of VEGFR2 in ECs to keep ECs quiescent, whereas Id1 and SCL/TAL1 rescue the 
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E2-2-mediated suppression of ECs (7,8). Migration, proliferation, survival, and 
differentiation in ECs are considerably altered during the process of EC activation. To 
investigate the effect of FAM96B on EC migration, we infected HUVECs with either 
GFP- or FAM96B-expressing adenoviruses prior to seeding the ECs on a 
fibronectin-coated filter (Fig. 3a). We then counted the number of ECs under the chamber. 
As seen in Figure 3b, FAM96B potentiated the EC migration. Again, the overexpression 
of FAM96B in HUVECs decreased the E2-2 protein (Fig. 3a). We also tested whether 
FAM96B affected cell proliferation and network formation in ECs after ECs were 
infected with either GFP- or FAM96B-expressing adenoviruses. Overexpression of 
FAM96B in ECs potentiated both the cell growth (Fig. 3c) and the formation of cord-like 
structures (Fig. 3d and 3e). Thus, these observations indicate that in contrast to E2-2, 
FAM96B has the ability to keep ECs active. 
Effect of FAM96B on the expression of E2-2- Because ectopic FAM96B seems to 
influence the expression of E2-2 protein in COS7 cells (Fig. 1a) and HUVECs (Fig. 3a), 
we further investigated whether the expression of E2-2 protein is attenuated by the 
ectopic expression of FAM96B. When Myc-FAM96B was overexpressed with Flag-E2-2 
in COS7 cells, the expression of Flag-tagged E2-2 was diminished with the increasing 
expression of Myc-FAM96B (Fig. 4a), and vice versa (Fig. 4b). Thus, the decrease of 
E2-2 expression mediated by FAM96B was not dependent on the tags. Furthermore, the 
ectopic expression of FAM96B decreased the endogenous E2-2 protein in NIH3T3 cells 
(Fig. 4c). Since E12/47 belongs to the E protein family, we also tested if FAM96B 
affected the expression of the E47 protein. Expectedly, the expression of E47 protein was 
also decreased by FAM96B to the same extent as that of E2-2. On the other hand, the 
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expression of neither Smad2 (Fig. 4d) nor c-myc (Suppl. Fig. 3) was altered by FAM96B. 
Therefore, this finding strongly suggests that FAM96B is able to specifically affect the 
protein expression of the E protein family. 
Exploration of the functional domain in FAM96B-To find the functional domain 
in FAM96B required for the decrease of E2-2 protein expression, we made two FAM96B 
mutants, termed FAM96B(42-121) and FAM96B∆ (42-121) (Fig. 5a). Then, we explored 
which part(s) of FAM96A can affect the expression of E2-2 protein. As seen in Fig. 5b, 
FAM96B(42-121), but not FAM96B∆ (42-121), could decrease the expression of E2-2 
even if the expression of FAM96B (42-121) was relatively lower than that of FAM96B∆ 
(42-121). Collectively, the domain from Asp42 to Ile121 in FAM96B is necessary for 
FAM96B to decrease the expression of E2-2.  
 
Discussion 
E protein family members such as E2-2 and E12/47 are widely expressed and act 
as either transcriptional activators or transcriptional repressors dependent on the 
partner(s) that the E protein family can interact with (25-28). E proteins are known to 
play key roles in the regulation of cell proliferation and differentiation. For example, 
E2-2 and E12/47 play critical roles in B-cell development and perturbed T-cell 
development (29-31). In our previous studies, E2-2 kept ECs quiescent, whereas the HLH 
proteins Id1 and SCL/TAL1 were capable of overcoming the inhibitory action of E2-2 on 
EC functions (7,8). In the present study, FAM96B, which is not a member of the HLH 
protein family, was found to decrease the expression of E2-2 protein in cells so as to 
perturb E2-2-mediated cellular responses such as transcriptional activities and EC 
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quiescence. The experiments using FAM96B mutants predicted that the middle region of 
FAM96B is critical for it to exhibit limited expression of E2-2 protein. Although 
FAM96B does not have any known conserved domains, the middle region of FAM96B 
shows similarity to ‘domain of unknown function 59 (DUF59)’ in prokaryotes. Thus, to 
the best of our knowledge, this is the first report to define the functional significance of 
DUF59. 
Since a number of proteins in cells can be degraded through either the 
proteasomal or the lysosomal pathways (32), we tried to investigate whether FAM96B 
can also decrease the expression of the E2-2 protein via these pathways. However, the 
decrease of E2-2 expression mediated by FAM96B was not rescued by inhibitors specific 
for either proteasomes or lysosomes (Suppl. Fig. 4 and 5). As another possibility, we 
checked the transcript of E2-2 with or without FAM96B in either the absence or the 
presence of actinomycin D. However, the transcript of E2-2 was not altered by FAM96B 
(data not shown). These results indicate the possibility that FAM96B can activate a 
certain protease(s) that targets E2-2. Because we currently do not know the exact 
mechanism by which FAM96B can diminish the expression of the E2-2 protein, several 
possibilities still need to be explored. Furthermore, it is interesting to analyze that 
FAM96B can be regulated at a transcriptional and/or a translational level by itself. 
In a previous study, we found that E2-2 interfered with EC activation while its 
interaction partners Id1 and SCL/TAL1 overcame the function of E2-2 and activated ECs 
(7,8). Besides, FAM96B was found as one of BMP-inducing genes like Id1 in our present 
study. Therefore, we assumed that FAM96B could also potentiate the function of ECs. 
Indeed, we were convinced that FAM96B can promote EC activation. Importantly, the 
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expression of endogenous E2-2 protein was diminished by FAM96B, demonstrating that 
FAM96B restricts the expression of E2-2 protein to control E2-2-mediated cellular 
responses in ECs. Our hypothesis can be further supported by the evidence that FAM96B 
could rescue the E2-2-mediated suppression of the VEGFR2 promoter. Thus, it is high 
possibility that the protein expression of VEGFR2 is influenced by FAM96B. This 
possibility will be tested in our further investigation. Since E2-2 is ubiquitously expressed 
in cells, it will be interesting to know if FAM96B regulates the function of E2-2 via the 
control of E2-2 expression in cell types other than ECs. Our preliminary study indicated 
that FAM96B could not compete with Id1 for the interaction with E2-2 despite the fact 
that both Id1 and FAM96B can associate with E2-2. Therefore, the function of E2-2 
might be fine-tuned at different steps within cells via the regulation of its protein 
expression, its DNA binding ability, and so forth. 
In conclusion, we discovered a novel mechanism by which FAM96B impairs the 
expression of E2-2 protein in ECs to potentiate EC activation. The identification of 
compounds that bolster E2-2 activity via the activation of FAM96B in ECs may provide 
an exciting opportunity to modulate tumor angiogenesis for therapeutic intervention. 
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Figure legends 
Fig. 1 Association between FAM96B and E2-2. (a) Interaction of Myc-E2-2 with 
Flag-FAM96B. Myc-E2-2 was cotransfected with Flag-FAM96B. Immnunoprecipitations 
were carried out with anti-Flag M5 antibody, and coimmunoprecipitated E2-2 was 
detected by Western blotting with anti-Myc9E10 antibody (upper panel). The expressions 
of Myc-E2-2 and Falg-FAM96B were evaluated by using anti-Myc9E10 antibody 
(middle panel) and anti-Flag M5 antibody (lower panel), respectively. (b) FAM96B 
colocalizes with E2-2 in the nucleus. MEECs were transiently transfected with 
Flag-FAM96B and Myc-E2-2. Flag-FAM96B and Myc-E2-2 were visualized with red 
and green, respectively, as described in the text. Colocalization of E2-2 with FAM96B 
appears as yellow. Nuclei were stained with DAPI. (c) Induction of FAM96B mRNA 
upon ALK6 activation. MEECs were infected with either LacZ- or ALK6ca-expressing 
adenoviruses. Then, RT-PCR was performed using sets of two specific primers for 
FAM96B (top panel), Id1 (2nd panel), Smad6 (3rd panel) and β-actin (4th panel). Both the 
expressions of Id1 and Smad6 were used as known BMP-inducible genes, whereas 
β-actin was used as a loading control. The expression of ALK6ca was detected with 
anti-HA antibody (bottom panel). 
 
Fig. 2 FAM96B counteracts E2-2-mediated luciferase activity. (a) FAM96B inhibits 
E2-2-induced MCKpfos-luc activity. CPAEs were transfected with MCKpfos-luc and 
different amounts of FAM96B and E2-2. (b) FAM96B relieves the inhibition of 
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pGL2b-VEGFR2-luc (-166bp/+267bp) activity by E2-2. CPAEs were transfected with 
pGL2b-VEGFR2-luc (-166bp/+267bp), FAM96B, and E2-2. 
 
Fig. 3 FAM96B potentiates EC activation. (a) The decrease of E2-2 expression in 
ECs. After the adenoviral infection, total lysates were prepared. Then, Western blotting 
was performed. Expression of endogenous E2-2 was evaluated with anti-E2-2 antibody 
(top panel). Myc-FAM96B was detected with anti-Myc9E10 antibody (2nd panel). As 
internal controls, GFP (3rd panel) and β-actin (lower panel) were visualized by using 
anti-GFP antibody and anti-β-actin antibody, respectively. (b) FAM96B activates EC 
migration. After adenoviral infection, HUVECs were seeded on the upper membrane of 
the Boyden chamber. After 24 h, cells were stained with crystal violet and the number of 
transmigrated cells was counted. (c) FAM96B enhances EC proliferation. After 
adenoviral infection, cells were labeled with [3H]-thymidine. Then, the 3H radioactivity 
incorporated into DNA was determined by liquid scintillation counting. (d) FAM96B 
potentiates the formation of cord-like structures on the Matrigel. Forty hours after 
adenoviral infection, HUVECs were seeded on the Matrigel. The images at 6 and 12 h 
time points are shown. The t test was adapted to analyze significant difference between 
GFP- and FAM96B-infected cells. (e) Areas of cord-like structures in Fig. 3d were 
measured by Image J. 
 
Fig. 4 Effect of FAM96B on the expression of E2-2. (a, b) Decrease of E2-2 protein 
by FAM96B. Different amounts of Myc-FAM96B (a) and Flag-FAM96B (b) were 
cotransfected with Flag-E2-2 (a) and Myc-E2-2 (b), respectively. After preparation of 
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total lysates, the expressions of Flag-E2-2 (a) and Myc-E2-2 (b) were evaluated by using 
anti-Flag M5 antibody and anti-Myc9E10 antibody, respectively (upper panel). The 
expression of FAM96B was detected with anti-Myc9E10 (a) and anti-Flag M5 antibodies 
(b) (middle panel). As a loading control, the expression of β-actin was observed with 
anti-β-actin antibody (lower panel). (c) Decrease of endogenous E2-2 protein by 
FAM96B. NIH3T3 cells were transfected with a different amount of Myc-FAM96B. 
After preparation of total lysates, endogenous E2-2 was detected with anti-E2-2 antibody 
(upper lane). The expression of FAM96B was detected with anti-Myc9E10 (middle 
panel). As a loading control, the expression of β-actin was observed with anti-β-actin 
antibody (lower panel). (d) Decrease of E47 protein by FAM96B. The different amounts 
of Myc-FAM96B were cotransfected with Flag-E2-2, Flag-E47, or Flag-Smad2. After 
preparation of total lysates, the expressions of Flag-E2-2 (top), Flag-E47 (middle), and 
Flag-Smad2 (lower) were evaluated by using anti-Flag M5 antibody (left panels). The 
expression of FAM96B was detected with anti-Myc9E10 antibody (right panel). 
 
Fig. 5 The middle domain in FAM96B is critical for its activity to decrease E2-2 
protein. (a) Mutants of FAM96B. (b) Degradation of E2-2 by FAM96B (42-121). The 
different amounts of either Myc-FAM96B(42-121) or Myc-FAM96B∆(42-121) were 
transfected with Flag-E2-2. After preparation of total lysates, Flag-E2-2 was detected 
with anti-Flag M5 antibody (upper lane). The expression of Myc-FAM96B(42-121) or 
Myc-FAM96B∆(42-121) was detected with anti-Myc9E10 (middle panel). Because the 
expression of Myc-FAM96B (42-121) was lower than that of Myc-FAM96B∆ (42-121), 
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two photos were taken, one with short exposure and one with long exposure. As a loading 
control, the expression of β-actin was observed with anti-β-actin antibody (lower panel). 
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Supplementary Figure legends 
Suppl. Fig. 1. Expression of E2-2 mRNA upon ALK6 activation. Mouse embryonic 
endothelial cells (MEECs) were infected with either LacZ- or ALK6ca-expressing 
adenoviruses. Then, RT-PCR was performed using sets of two specific primers for E2-2 
(5’-GTGGCCATTGAAGGTTTGTG-3’/3’-TCGTGAAAGGGATCGAGGAA-5’) (top 
panel), Smad7 
(5’-TCCAGATGCTGTACCTTCCT-3’/3’-AAATGTTGGCGTCGTCAATG-5’) (middle 
panel) and β-actin 
(5’-TGAACCCTAAGGCCAACCGTG-3’/3’-GCTCATAGCTCTTCTCCAGGG-5’) 
(bottom panel). Smad7 was used as a known BMP-inducible gene, whereas β-actin was 
used as a loading control. 
 
Suppl. Fig. 2. Effect of VEGF on expression of FAM96B. MEECs were stimulated 
with VEGF for 0, 1, 2 and 6 h. Then, RT-PCR was performed using sets of two specific 
primers for VEGFR2 
(5’-AGCTGTCGCTCTGTGGTTCT-3’/3’-CGTTTTGTGAGTGGTAAGGG-5’) (top 
panel). Other primer sets were described in Suppl. Table I and Suppl. Fig. 1. 
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Suppl. Fig. 3. Effect of FAM96B on expression of c-myc protein. The different 
amounts of Myc-FAM96B were cotransfected with Flag-c-myc in COS7 cells. After 
preparation of total lysates, the expression of Flag-c-myc was evaluated by using 
anti-Flag M5 antibody (upper panel). The expression of FAM96B was detected by using 
anti-Myc9E10 antibody (middle panel). As a loading control, the expression of β-actin 
was observed with anti-β-actin antibody (lower panel). 
 
Suppl. Fig, 4. Effect of proteasome inhibitors on FAM96B-mediated decrease of 
E2-2 protein. Different amounts of Myc-FAM96B were cotransfected with Flag-E2-2 in 
COS7 cells. Four hours before the preparation of total lysates, proteasome inhibitors (10 
µM MG-132 and 2 µM lactacystin) were added to the medium. DMSO was used as a 
mock stimulation. The expression of Flag-E2-2 was evaluated by using anti-Flag M5 
antibody (upper panel). The expression of FAM96B was detected by using anti-Myc9E10 
antibody (middle panel). As a loading control, the expression of β-actin was observed 
with anti-β-actin antibody (lower panel). 
 
Suppl. Fig. 5. Effect of a lysosome inhibitor on FAM96B-mediated decrease of E2-2 
protein. Different amounts of Myc-FAM96B were cotransfected with Flag-E2-2 in 
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COS7 cells. Four hours before the preparation of total lysates, a lysosome inhibitor (50 
µg/mL chloroquine) was added to the medium. The expression of Flag-E2-2 was 
evaluated by using anti-Flag M5 (upper panel) antibody. The expression of FAM96B was 
detected by using anti-Myc9E10 antibody (middle panel). As a loading control, the 
expression of β-actin was observed with anti-β-actin antibody (lower panel). 
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Human cDNA 　	 Sequence 
FAM96B (+) CGAGGAAGATGAGGAAGTGC 
　	 (-) CGCTCCTTATCTGCAAGTTG 
Id1 (+) ACTTGGTCTGTCGGAGCAAA 
　	 (-) CAGCGACACAACTAGCGATC 
Smad6 (+) TGTTGCAACCCCTACCACTT 
　	 (-) GTCGTTCTAGCCAAAACCGT 
β-actin (+) GCTCATAGCTCTTCTCCAGGG 
　	 (-) GTGCCAACCGGAATCCCAAGT 
Suppl. Table I PCR primers to amplify mouse cDNAs 
L: length of PCR fragment; AT: annealing temperature 
